Increase in Nosocomial Infections due to Immuno-compromised Patients to Drive Antifungal Drugs Market Growth
Fungal infections have become a major public health concern around the world in recent years. The increasing occurrences of cancers, increase in hematopoietic stem cell transplantation, and other factors result in immune system weakness leading to rise in nosocomial infections. According to the Centers for Disease Control and Prevention (CDC), globally, 1.7 million hospitalized patients suffered from Nosocomial infections while being treated for other health issues in 2019, and more than 98,000 individuals die due to co-morbidities. This number saw an unexpected increase, by an average of 40%, in 2020 due to the Covid-19 pandemic. Such many patients getting affected by Nosocomial Infections is likely to boost the antifungal drugs market growth in the coming years.
The increase in the number of admissions in the intensive care unit and the lack of proper healthcare infrastructure in the middle and low-income countries will be a major boost for the Nosocomial infection treatment. According to the World Health Organization (WHO), roughly 30% of patients in intensive care units in high-income countries have at least one healthcare-associated infection, whereas the frequency of intensive care-acquired infection is 2-3 times higher in middle to low-income nations. This factor is likely to increase the demand for anti-fungal drugs, especially in the intensive care unit.
Broad-spectrum Activity of Azoles to Drive Antifungal Drugs Market Growth
Azoles are expected to be the leading segment in the forecast period due to their fungicidal capabilities and generate higher revenues. More fungal diseases and infections are treated with synthetic azoles and semi-synthetic substances. Thrush, yeast infection, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, fungal infections, systemic mycosis, and seborrheic dermatitis are all treated with these medications. The azole group has a wide range of activities, and higher safety criteria. Medication has fewer adverse effects, fewer medication interactions, and better absorption and distribution qualities. The benefits of azoles will uplift the growth outlook of antifungal drugs market.
Increased Prevalence of Infectious Diseases Augurs Well for Antifungal Drugs Market
The expansion of antifungal drugs market can be attributed to the rising prevalence of infectious diseases. The rise in prevalence has increased clinical urgency to increase the use of these medications, as well as accelerate the development of novel drugs with FDA fast-track authorisation. Additionally, the presence of established pharmaceutical businesses, who are continually pushing for extensive commercialisation of their products and expanding their geographical reach, is expected to be a vital element in amplifying the regional market's expansion. For instance, the U.S. Food and Medicine Administration accepted Scynexis Inc.'s application for its vaginal yeast infection drug ibrexafungerp on December 7, 2020, and gave the application priority review status. The FDA also granted the medication qualifying infectious disease product status, or QIDP, as well as fast-track designation. Such a high prevalence of drug trials and the latest drug innovations in the region will propel the growth of the market.
The North American antifungal drugs market is likely to remain dominated by the United States. The increased knowledge of fungal infections, antifungal disorders, and increased government and business organizations are all contributing to market expansion. The introduction of a number of high-quality, low-cost pharmaceuticals is hastening antifungal drugs market expansion. Additionally, the growing number of yeast infections in the region due to the hectic lifestyle and the increased humidity in the environment will boost the market growth. According to CDC, there were a total of 3,648,715 Candida infections in 2020 in the United States out of which 26,735 required hospitalizations. This factor is anticipated to drive antifungal drugs market in the United States.
The market for antifungal drugs in the Asia Pacific is expected to grow at the fastest rate during the forecast period. The presence of a large target population base, rising disposable income, drug availability, and significant unmet clinical requirements all contribute to the expansion of the regional market. As a result, global businesses are concentrating on significant R&D expenditure as well as commercialising branded pharmaceuticals at a reduced price in the region. Due to the huge number of generic manufacturers and increased government initiatives in this region, Asia Pacific is predicted to rise throughout the forecast period. Additionally, the development of healthcare infrastructure will accelerate the market's growth rate in this region.
Antifungal Drugs Market: Competitive Landscape
In June 2021, Posaconazole, a novel triazole antifungal drug from Cadila Pharmaceuticals, is effective against a wide spectrum of invasive fungal illnesses. The medication was also suggested as a second-line treatment for Mucormycosis. Posaconazole inhibits fungus growth and has a favorable safety profile. Even with long-term use, serious negative effects are uncommon. On the other hand, in June 2021, Scynexis stated that the US Food and Drug Administration had approved Brexafemme for the treatment of vaginal yeast infections.
Few of the players in the antifungal drugs market include Scynexis, Inc., Pfizer, Inc., Helix Biomedix, Gilead Sciences, Inc., Astellas Pharma, Inc., GSK plc, Sequella, Inc., Novartis AG, Leadiant Biosciences, Inc., and Sun Pharmaceutical Industries, Ltd.
Regional Classification of the Global Antifungal Drugs Market is Listed Below:
North America
- U.S.
- Canada
Europe
- Germany
- France
- Spain
- U.K.
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Southeast Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC
- South Africa
- Rest of Middle East & Africa
1. Executive Summary
1.1. Global Antifungal Drugs Market Snapshot
1.2. Key Market Trends
1.3. Future Projections
1.4. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.1.1. Driver A
2.2.1.2. Driver B
2.2.1.3. Driver C
2.2.2. Restraints
2.2.2.1. Restraint 1
2.2.2.2. Restraint 2
2.2.3. Market Opportunities Matrix
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. Covid-19 Impact Analysis
2.6. Government Regulations
2.7. Economic Analysis
2.8. PESTLE
3. Global Antifungal Drugs Market Outlook, 2018 - 2030
3.1. Global Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
3.1.1. Key Highlights
3.1.1.1. Imidazole
3.1.1.2. Polyenes
3.1.1.3. Allylamines
3.1.1.4. Echinocandins
3.1.1.5. Other
3.2. Global Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
3.2.1. Key Highlights
3.2.1.1. Oral
3.2.1.2. Topical
3.2.1.3. Parenteral
3.2.1.4. Other
3.2.2. BPS/Market Attractiveness Analysis
3.3. Global Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
3.3.1. Key Highlights
3.3.1.1. Candidiasis
3.3.1.2. Dermatophytosis
3.3.1.3. Aspergillosis
3.3.1.4. Coccidioidomycosis
3.3.1.5. Other
3.3.2. BPS/Market Attractiveness Analysis
3.4. Global Antifungal Drugs Market Outlook, by Region, Value (US$ Mn), 2018 - 2030
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
3.4.2. BPS/Market Attractiveness Analysis and trends, forming the crux of this section.
4. North America Antifungal Drugs Market Outlook, 2018 - 2030
4.1. North America Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
4.1.1. Key Highlights
4.1.1.1. Imidazole
4.1.1.2. Polyenes
4.1.1.3. Allylamines
4.1.1.4. Echinocandins
4.1.1.5. Other
4.2. North America Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
4.2.1. Key Highlights
4.2.1.1. Candidiasis
4.2.1.2. Dermatophytosis
4.2.1.3. Aspergillosis
4.2.1.4. Coccidioidomycosis
4.2.1.5. Other
4.3. North America Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
4.3.1. Key Highlights
4.3.1.1. Oral
4.3.1.2. Topical
4.3.1.3. Parenteral
4.3.1.4. Other
4.4. North America Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
4.4.1. Key Highlights
4.4.1.1. U.S.
4.4.1.2. Canada
4.4.2. BPS/Market Attractiveness Analysis
5. Europe Antifungal Drugs Market Outlook, 2018 - 2030
5.1. Europe Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
5.1.1. Key Highlights
5.1.1.1. Imidazole
5.1.1.2. Polyenes
5.1.1.3. Allylamines
5.1.1.4. Echinocandins
5.1.1.5. Other
5.2. Europe Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
5.2.1. Key Highlights
5.2.1.1. Candidiasis
5.2.1.2. Dermatophytosis
5.2.1.3. Aspergillosis
5.2.1.4. Coccidioidomycosis
5.2.1.5. Other
5.3. Europe Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
5.3.1. Key Highlights
5.3.1.1. Oral
5.3.1.2. Topical
5.3.1.3. Parenteral
5.3.1.4. Other
5.4. Europe Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
5.4.1. Key Highlights
5.4.1.1. Germany
5.4.1.2. France
5.4.1.3. U.K.
5.4.1.4. Italy
5.4.1.5. Spain
5.4.1.6. Russia
5.4.1.7. Rest of Europe
5.4.2. BPS/Market Attractiveness Analysis
6. Asia Pacific Antifungal Drugs Market Outlook, 2018 - 2030
6.1. Asia Pacific Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018-2030
6.1.1. Key Highlights
6.1.1.1. Imidazole
6.1.1.2. Polyenes
6.1.1.3. Allylamines
6.1.1.4. Echinocandins
6.1.1.5. Other
6.2. Asia Pacific Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
6.2.1. Key Highlights
6.2.1.1. Candidiasis
6.2.1.2. Dermatophytosis
6.2.1.3. Aspergillosis
6.2.1.4. Coccidioidomycosis
6.2.1.5. Others
6.3. Asia Pacific Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
6.3.1. Key Highlights
6.3.1.1. Oral
6.3.1.2. Topical
6.3.1.3. Parenteral
6.3.1.4. Other
6.4. Asia Pacific Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
6.4.1. Key Highlights
6.4.1.1. China
6.4.1.2. Japan
6.4.1.3. South Korea
6.4.1.4. India
6.4.1.5. Southeast Asia
6.4.1.6. Rest of Asia Pacific
6.4.2. BPS/Market Attractiveness Analysis
7. Latin America Antifungal Drugs Market Outlook, 2018 – 2030
7.1. Latin America Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
7.1.1. Key Highlights
7.1.1.1. Imidazole
7.1.1.2. Polyenes
7.1.1.3. Allylamines
7.1.1.4. Echinocandins
7.1.1.5. Other
7.2. Latin America Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
7.2.1. Key Highlights
7.2.1.1. Candidiasis
7.2.1.2. Dermatophytosis
7.2.1.3. Aspergillosis
7.2.1.4. Coccidioidomycosis
7.2.1.5. Other
7.3. Latin America Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018-2030
7.3.1. Key Highlights
7.3.1.1. Oral
7.3.1.2. Topical
7.3.1.3. Parenteral
7.3.1.4. Other
7.4. Latin America Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
7.4.1. Key Highlights
7.4.1.1. Brazil
7.4.1.2. Mexico
7.4.1.3. Rest of Latin America
7.4.2. BPS/Market Attractiveness Analysis
8. Middle East & Africa Antifungal Drugs Market Outlook, 2018 - 2030
8.1. Middle East & Africa Antifungal Drugs Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2030
8.1.1. Key Highlights
8.1.1.1. Imidazole
8.1.1.2. Polyenes
8.1.1.3. Allylamines
8.1.1.4. Echinocandins
8.1.1.5. Other
8.2. Middle East & Africa Antifungal Drugs Market Outlook, by Disease Indication, Value (US$ Mn), 2018 - 2030
8.2.1. Key Highlights
8.2.1.1. Candidiasis
8.2.1.2. Dermatophytosis
8.2.1.3. Aspergillosis
8.2.1.4. Coccidioidomycosis
8.2.1.5. Other
8.3. Middle East & Africa Antifungal Drugs Market Outlook, by Dosage form Application, Value (US$ Mn), 2018 - 2030
8.3.1. Key Highlights
8.3.1.1. Oral
8.3.1.2. Topical
8.3.1.3. Parenteral
8.3.1.4. Other
8.4. Middle East & Africa Antifungal Drugs Market Outlook, by Country, Value (US$ Mn), 2018 - 2030
8.4.1. Key Highlights
8.4.1.1. GCC
8.4.1.2. South Africa
8.4.1.3. Rest of Middle East & Africa
8.4.2. BPS/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Scynexis, Inc.
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
(*Note: Above details would be available for below list of companies based on availability)
9.3.2. Pfizer, Inc.
9.3.3. Novartis AG
9.3.4. Helix Biomedix
9.3.5. Sequella, Inc.
9.3.6. GILEAD SCIENCES, INC.
9.3.7. Leadiant Biosciences, Inc.
9.3.8. Sun Pharmaceutical Industries Ltd.
9.3.9. Astellas Pharma, Inc.
9.3.10. GSK plc
9.3.11. Other
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2018 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
Drug Class Coverage |
|
|
Disease Indication Coverage |
|
|
Dosage form Coverage |
|
|
Geographical Coverage |
|
|
Leading Market Companies |
|
|
Report Highlights |
Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Drug Class, Disease Indication, Dosage form, Region, Country-Wise Trends & Analysis, COVID-19 Impact Analysis (Demand & Supply), Key Market Trends |
Quality assured
